Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ALBO

Albireo Pharma (ALBO) Stock Price, News & Analysis

Albireo Pharma logo

About Albireo Pharma Stock (NASDAQ:ALBO)

Key Stats

Today's Range
$43.99
$44.90
50-Day Range
$43.50
$44.95
52-Week Range
$16.02
$45.23
Volume
1.24 million shs
Average Volume
704,539 shs
Market Capitalization
$913.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Stock News Headlines

Prospect Park II in Fort Lauderdale
Musk Says ‘Dollar Will Be Worth Nothing…’
Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…
ALBO Historical Data
ALBO Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO)
See More Headlines

ALBO Stock Analysis - Frequently Asked Questions

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $3.28. The biopharmaceutical company had revenue of $3.66 million for the quarter, compared to the consensus estimate of $22.33 million. Albireo Pharma had a negative net margin of 228.51% and a negative trailing twelve-month return on equity of 97.13%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Albireo Pharma investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW) and Devon Energy (DVN).

Company Calendar

Last Earnings
11/04/2021
Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALBO
Employees
130
Year Founded
2003

Profitability

Net Income
$-34,030,000.00
Net Margins
-228.51%
Pretax Margin
-235.11%

Debt

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$9.11 per share

Miscellaneous

Free Float
19,273,000
Market Cap
$913.91 million
Optionable
Optionable
Beta
1.03

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:ALBO) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners